Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
An Adaptive, Randomized, Double-blind, Dose Exploration, Parallel Group, Placebo Controlled, Multicenter Phase 2 Trial to Evaluate the Efficacy, Safety and Tolerability of LNP023 in Combination With Standard-of-care With and Without Oral Corticosteroids in Patients With Active Lupus Nephritis Class III-IV, +/- V
The overall purpose of this two-part study is to evaluate the efficacy, safety and tolerability of iptacopan (LNP023) in addition to standard of care treatment.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
The overall purpose of this two-part study is to evaluate the efficacy, safety and tolerability of iptacopan (LNP023) in addition to standard of care treatment.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Santa Fe, Argentina, S3000EPV
- Novartis Investigative Site
-
-
-
-
-
Salvador, Brazil, 40323-010
- Novartis Investigative Site
-
-
Estado de Bahia
-
Salvador, Estado de Bahia, Brazil, 40150-150
- Novartis Investigative Site
-
-
Minas Gerais
-
Belo Horizonte, Minas Gerais, Brazil, 30150-221
- Novartis Investigative Site
-
-
São Paulo
-
São Paulo, São Paulo, Brazil, 05403-000
- Novartis Investigative Site
-
São Paulo, São Paulo, Brazil, 04038-002
- Novartis Investigative Site
-
-
-
-
-
Shenzhen, China, 518036
- Novartis Investigative Site
-
-
Guangxi
-
Nanning, Guangxi, China, 530022
- Novartis Investigative Site
-
-
Ningxia
-
Yinchuan, Ningxia, China, 750004
- Novartis Investigative Site
-
-
-
-
-
Montería, Colombia, 230004
- Novartis Investigative Site
-
-
Atlántico
-
Barranquilla, Atlántico, Colombia, 080020
- Novartis Investigative Site
-
-
Cundinamarca
-
Bogota, Cundinamarca, Colombia, 111411
- Novartis Investigative Site
-
-
Santander Department
-
Bucaramanga, Santander Department, Colombia, 680003
- Novartis Investigative Site
-
-
-
-
-
Marseille, France, 13005
- Novartis Investigative Site
-
Nantes, France, 44093
- Novartis Investigative Site
-
-
-
-
-
Mainz, Germany, 55131
- Novartis Investigative Site
-
-
Lower Saxony
-
Braunschweig, Lower Saxony, Germany, 38126
- Novartis Investigative Site
-
-
-
-
Hong Kong
-
Hong Kong, Hong Kong, Hong Kong, 999077
- Novartis Investigative Site
-
-
-
-
Kerala
-
Kozhikode, Kerala, India, 673008
- Novartis Investigative Site
-
-
National Capital Territory of Delhi
-
New Delhi, National Capital Territory of Delhi, India, 110029
- Novartis Investigative Site
-
-
Telangana
-
Hyderabad, Telangana, India, 500082
- Novartis Investigative Site
-
-
-
-
-
Selangor Darul Ehsan, Malaysia, 68100
- Novartis Investigative Site
-
-
Pahang
-
Kuantan, Pahang, Malaysia, 25100
- Novartis Investigative Site
-
-
Perak
-
Taiping, Perak, Malaysia, 34000
- Novartis Investigative Site
-
-
-
-
-
Aguascalientes, Mexico, 20230
- Novartis Investigative Site
-
Veracruz, Mexico, 91900
- Novartis Investigative Site
-
-
Tamaulipas
-
Tampico, Tamaulipas, Mexico, 89440
- Novartis Investigative Site
-
-
Yucatán
-
Mérida, Yucatán, Mexico, 97070
- Novartis Investigative Site
-
-
-
-
-
Quezon, Philippines, 1102
- Novartis Investigative Site
-
-
National Capital Region
-
Makati City, National Capital Region, Philippines, 1218
- Novartis Investigative Site
-
-
-
-
-
Coimbra, Portugal, 3004-561
- Novartis Investigative Site
-
-
-
-
Singapore
-
Singapore, Singapore, Singapore, 308433
- Novartis Investigative Site
-
-
-
-
Melikgazi
-
Kayseri, Melikgazi, Turkey (Türkiye), 38039
- Novartis Investigative Site
-
-
Yenimahalle
-
Ankara, Yenimahalle, Turkey (Türkiye), 06500
- Novartis Investigative Site
-
-
Yenisehir
-
Mersin, Yenisehir, Turkey (Türkiye), 33110
- Novartis Investigative Site
-
-
-
-
-
Cambridge, United Kingdom, CB2 0QQ
- Novartis Investigative Site
-
-
-
-
California
-
San Bernardino, California, United States, 92408
- Loma Linda University
-
-
Illinois
-
Hinsdale, Illinois, United States, 60521
- Nep Assoc of Northern Illinois
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Unequivocally positive ANA test result and/or a positive anti dsDNA at screening Active biopsy-proven lupus nephritis within 3 months of screening demonstrating Class III or IV lupus nephritis with or without co-existing features of Class V lupus nephritis.
Documentation of active renal disease at the time of screening necessitating the commencement of therapy with corticosteroids in combination with MMF/MPS.
eGFR ≥ 30 ml/min/1.73 m2 Vaccination against Neisseria meningitidis and Streptococcus pneumoniae infections Vaccination against Haemophilus influenzae infection Supportive care including stable dose regimen of anti-malarials (e.g. hydroxychloroquine) unless contraindicated, ACEi or ARB at either locally approved maximal daily dose or the maximally tolerated dose (per investigators' judgement) at screening, as per the local clinical practice. Doses should remain stable throughout the study.
First presentation or flare of lupus nephritis.
Exclusion Criteria:
Induction treatment with cyclophosphamide within 3 months of planned treatment for this study; treatment with calcineurin inhibitors within the previous 3 months prior to randomization.
Presence of rapidly progressive glomerulonephritis (RPGN) as defined by 50% decline in eGFR within 3 months prior to screening.
Renal biopsy presenting with interstitial fibrosis/tubular atrophy (IF/TA) or glomerulosclerosis of more than 50%, or which in the opinion of the investigator is such that it precludes likely response to immunosuppressive therapy.
Participants being treated with systemic corticosteroids (>5 mg/day prednisone or equivalent) for indications other than SLE or LN e.g. acute asthma, inflammatory bowel disease.
Participants being treated with systemic corticosteroids for SLE or LN will be excluded if they have taken more than an average of 15 mg/day prednisone (or equivalent) in the previous 4 weeks and more than an average of 30 mg/day in the previous 1 week Receipt of more than a total dose of 1000 mg equivalent i.v. pulse methylprednisolone (cumulative dose) within 2 weeks prior to enrollment (and at enrollment)
Other protocol-defined inclusion/exclusion criteria may apply
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Iptacopan + standard of care (part 1)
Iptacopan + standard of care |
Taken for 52 Weeks
Other Names:
|
|
Placebo Comparator: Placebo matching iptacopan + standard of care (part 1)
Placebo matching iptacopan standard of care |
Taken for 52 Weeks |
|
Active Comparator: Iptacopan + standard of care (part 2)
Iptacopan + standard of care |
Taken for 52 Weeks
Other Names:
|
|
Active Comparator: Iptacopan + placebo (part 2)
Iptacopan + placebo standard of care |
Taken for 52 Weeks
Other Names:
|
|
Active Comparator: Placebo matching iptacopan + standard of care (part 2)
Placebo matching iptacopan + standard of care |
Taken for 52 Weeks |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Part 1 and 2: Proportion of patients achieving Complete Renal Response (CRR) at week 24 in the absence of renal flares
Time Frame: Baseline and week 24
|
Part 1: To evaluate the proportion of patients achieving complete renal response with iptacopan treatment "A" plus standard of care, compared to treatment alone Part 2: To evaluate the proportion of patients achieving complete renal response with Iptacopan treatment "B" plus standard of care, compared to treatment "D" alone Part 2: To evaluate the proportion of patients achieving complete renal response with Iptacopan treatment "C" plus standard of care, compared to treatment "D" alone Complete Renal Response is defined as meeting the following criteria: estimated glomerular filtration rate (eGFR) ≥ 90 mL/min/1.73 m2 or no less than 85% of baseline value, and 24h urine protein-to-creatinine ratio (UPCR) ≤ 0.5 g/g. |
Baseline and week 24
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Parts 1 and 2: Proportion of patients achieving CRR or PRR in the absence of renal flares
Time Frame: Baseline, week 24, week 52
|
Proportion of patients achieving complete renal response or partial renal response |
Baseline, week 24, week 52
|
|
Proportion of patients achieving ≥25% UPCR reduction in the absence of renal flares compared to baseline at week 24
Time Frame: Baseline, week 24 week 52
|
Frequency of renal flares between weeks 24 and 52 |
Baseline, week 24 week 52
|
|
Log-transformed ratio to baseline of 24h UPCR at week 24
Time Frame: Baseline week 24
|
Dose exposure response for reduction in proteinurea. (each 24h urine protein-to-creatinine ratio value will based on two 24 urine collections sampled within 10 days before the respective study visit) |
Baseline week 24
|
|
Change from baseline FACIT-Fatigue Score
Time Frame: Weeks 24 and 52
|
Measure fatigue in patients |
Weeks 24 and 52
|
|
Change from baseline in SLEDAI-2K score at weeks 24 and 52
Time Frame: Weeks 24 and 52
|
Measure disease activity in SLE |
Weeks 24 and 52
|
|
Change from baseline in BILAG-2004 score at weeks 24 and 52
Time Frame: Weeks 24 and 52
|
Measure disease activity |
Weeks 24 and 52
|
|
Time-to-Complete Renal Response (CRR) based on first morning void(FMV) urine samples
Time Frame: Week 24 and Week 52
|
Measurement of time to complete renal response based on urine samples |
Week 24 and Week 52
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Urogenital Diseases
- Male Urogenital Diseases
- Kidney Diseases
- Urologic Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Connective Tissue Diseases
- Autoimmune Diseases
- Immune System Diseases
- Urination Disorders
- Urological Manifestations
- Glomerulonephritis
- Nephritis
- Pathological Conditions, Signs and Symptoms
- Skin and Connective Tissue Diseases
- Signs and Symptoms
- Lupus Erythematosus, Systemic
- Lupus Nephritis
- Proteinuria
- Health Services Administration
- Health Care Quality, Access, and Evaluation
- Quality of Health Care
- Quality Indicators, Health Care
- Standard of Care
- iptacopan
Other Study ID Numbers
Other Study ID Numbers
- CLNP023K12201
- 2021-002046-33 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.